

November 28, 2022

National Stock Exchange of India Limited, Listing Department Exchange Plaza, 5th Floor, Bandra (E), Mumbai-400051

Symbol: **ORCHIDPHARMA**

BSE Limited

Listing Department Corporate Relationship Department

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort, Mumbai-400001

Scrip Code: 524372

<u>Subject</u>: <u>Disclosure under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith half yearly disclosure on Related Party Transactions, on a consolidated basis, prepared in accordance with the applicable accounting standards for the period ended September 30, 2022.

The enclosed disclosure will also be made available on the website of the Company i.e. www.orchidpharma.com

You are requested to take the above on record.

Thanking You, For **Orchid Pharma Limited**

MARINA Digitally signed by MARINA PETER Date: 2022.11.28 17:26:00 +05'30'

Marina Peter Company Secretary Encl. As above

bount R.L. in Lakha] Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed enith/subsidiary. These debils need to be disclosed only once, during the reporting period when such transaction was undertalen.	s are due to Details of the named indebtedness is incurred to Details of the sare result of the make or give saus, inter-corporate deposits, advances or investments	Closing Nature of Cost Tenure Nature (loan/) Interest Rate Indebtedness (loan/) Interest Rate Indebtedness (loan/) Interest Rate Interest	0000	0000	3207.05	0000	0.89	15.83	492.86	0000	405.00	0.23	3839.28	31.12	00'0	900	000	0000	00'0	00'00	0000	000
(Amount	Value of in case monies are due to transaction during aither party as a result of the the reporting transaction	Opening C balance b	0.00	674.03	3472.27	0000	0000	0,00	492.90	0000	0000	5.29	3639.28	31.12	0000	000	0000	0000	0000	0.00	0 000	
	Value of the related party transaction as approved by the sudit committee		3500.00	2696.13 2696.13	13000.00 7211.40	140.00 63.96	1600.00 531.52	500.00 15.83	1971.62 1971.62	94.00 43.55	5500.00 405.00	500.00 1.35	0.00	000	37.56	37.56 V	330	0.80	0.85	1.00	0.55	
	Type of related party transaction	1.	Purchase of goods or services	Purchase of fixed assets	Purchase of goods or services	Lease of Land and Buildings	Sale of goods or services	Sale of goods or services	Purchase of flued assets	Lesse of Land and Buildings	loan	Sale of goods or services	Yrade Receivable	Trade Payable	Remuneration and Short term benefits the Key Managerial Personnel(Managing Director, Whole time	Remuneration and Short term benefits to Key Managerial Personnel(Managing Director, Whole time Director and Company Secretary)	Remuneration and Short term benefits to Key Managerial Personnel(Managing Director, Whole time Director and Company Secretary)	Sitting fee to Non- Executive Directors	Sitting fee to Nan- Executive Directors	Sitting fee to Non- Executive Directors	Sitting fee to Non- Executive Directors	
		Relationship of the counterparty with the listed entity or its subsidiary	Holding Company	Holding Company	Related Party under Section 2(76)(N) of the Companies Act,2013	Holding Company	Holding Company	Related Party under Section 2(76)(iii) of the Companies Act,2013	Related Party under Section 2(76)(ii) of the Companies Act,2013	Related Party under Section 2(76)(iii) of the Companies Act,2013	Subsidiary Company	Associate Company	Subsidiary Company	Subsidiary Company	Managing Director	Whole Time Director	Company Secretary	Non-Enecutive Director	Independent Director	Independent Director	Independent Director	
	Details of the counterparty	Name PAN	Dhanuka Laboratories limited	Dhanusa taboratories Umited	Otsuka Chemical (India) Pvt. Ltd.	Dhanuka Laboratories Limited	Dhanuka Laboratories Limited	Synmedic Laboratories	Symmedic Laboratories	Symmedic Laboratories	Orchid Bio-Phierna Umited	Orbion Pharmaceuticals Private Limited	Orchid Pharma Inc	Orchid Europe Limited	Shri Manish Dhanuka	Shri Mridul Dhanuka	Ms. Nikita K	Shri Arun Kumar Dhanuka	Dr. Dharam Vir	Shri Manoj Kumar Goyal	Shri Mudit tandon	Comp. Manual.
	Details of the party (listed entity /subsidiary) entering into the transaction	Name PAN	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orthid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited	Orchid Pharma Limited		Orchid Pharma Limited	Orchid Pharma Limited	

S. K. S. W. Sunil Kumar Gupta Chief Financial Officer

CHIO PHARMING OPPOSITION OF THE PHARMING OPPOSITION OF THE PHARMING OPPOSITION OF THE PHARMING OF THE PHARMING